Xilio Therapeutics (XLO) to Release Quarterly Earnings on Thursday

Xilio Therapeutics (NASDAQ:XLO) is expected to post its Q3 2025 results before the market opens on Thursday, November 6th. Analysts expect Xilio Therapeutics to post earnings of ($0.03) per share for the quarter. Individuals can find conference call details on the company’s upcoming Q3 2025 earningreport page for the latest details on the call scheduled for Thursday, November 6, 2025 at 9:00 AM ET.

Xilio Therapeutics (NASDAQ:XLO) last posted its earnings results on Thursday, August 14th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.08). Xilio Therapeutics had a negative net margin of 374.79% and a negative return on equity of 399.15%. The company had revenue of $8.21 million during the quarter, compared to analyst estimates of $8.21 million. On average, analysts expect Xilio Therapeutics to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Xilio Therapeutics Stock Performance

XLO stock opened at $0.81 on Thursday. Xilio Therapeutics has a 1 year low of $0.62 and a 1 year high of $1.70. The firm has a market cap of $41.98 million, a P/E ratio of -1.07 and a beta of -0.07. The stock has a 50-day simple moving average of $0.76 and a 200-day simple moving average of $0.75.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the company. Leerink Partnrs upgraded Xilio Therapeutics to a “strong-buy” rating in a research note on Wednesday, August 6th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Xilio Therapeutics in a research note on Wednesday, October 8th. Leerink Partners started coverage on Xilio Therapeutics in a research note on Wednesday, August 6th. They set an “outperform” rating and a $2.00 price objective for the company. Finally, Wall Street Zen downgraded Xilio Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, August 16th. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Xilio Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $3.00.

Xilio Therapeutics Company Profile

Xilio Therapeutics, Inc, a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company’s checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors.